Oncology Pharmaceuticals / Tumor-Targeted Drug Development
Strategic Profile
Allist has established itself as a specialized oncology player with core competencies in lung cancer therapeutics. The company leverages both proprietary drug development capabilities and strategic in-licensing agreements to expand its pipeline, positioning itself to compete in the global pharmaceutical market while maintaining strong domestic commercialization channels.
Cyborg Score Rationale
Allist demonstrates solid fundamentals with two approved Class I innovative drugs, growing market capitalization (~47.4B CNY), and successful commercialization of Furmonertinib in the lung cancer space. The company benefits from strategic partnerships and a differentiated pipeline, though it remains smaller than major international pharma competitors.
Top Insights
Furmonertinib has achieved remarkable commercial success with strong sales performance since launch and multiple indication expansion potential
Recent out-licensing deal with Jacobio Pharma (August 2024) brings KRAS G12C and SHP2 inhibitors to expand oncology portfolio beyond EGFR-targeted therapies
Company maintains 130+ specialized researchers in Shanghai's Medicine Valley with complete drug development infrastructure from discovery through post-approval studies
Recent priority review approval for zosuquidar mesylate for EGFR exon 20 insertion NSCLC demonstrates continued pipeline advancement
Named Competitors
Osimertinib — Leading EGFR-TKI for NSCLC
Afatinib — EGFR-TKI for advanced lung cancer
Glecirasib — KRAS G12C inhibitor for lung cancer
Recent Developments
(July 2025) Furmonertinib second-line NSCLC indication included in priority review process with reported 16-month mPFS in 240mg dose group
(August 2024) In-licensed KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 from Jacobio Pharma for China rights
(July 2025) Zosuquidar mesylate added to CDE priority evaluation list for EGFR exon 20 insertion NSCLC treatment
Open the full interactive Shanghai Allist Pharmaceuticals Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.